- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05059782
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
September 25, 2021 updated by: Liu Zi, Health Science Center of Xi'an Jiaotong University
In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The recurrent or refractory ovarian cancer tends to recur repeatedly at increasingly short intervals, making treatment more and more difficult.Patients often have limited physical capacity to undergo repeated systematic treatment.
Currently, NCCN( national comprehensive cancer network )guidelines recommend palliative radiotherapy in patients with local recurrence of ovarian cancer.
With the progress of IMRT( intensity modulated radiation therapy ), SBRT ( stereotactic body radiation therapy ) and other radiotherapy technologies, better local tumor control rate can also be achieved, while minimizing the damage to surrounding normal tissues.
In this study, the patients will be divided into groups according to their wishes: group A (drug therapy alone), group B (radiotherapy alone), and group C (radiotherapy plus drug therapy).The researchers sought to explore the the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients in different groups after treatment by inviting multiple centers to participate in the study.
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zi Liu, Ph.d
- Phone Number: 86-18991232167
- Email: liuzmail@163.com
Study Contact Backup
- Name: Jing Zhang, M.D
- Phone Number: 86-18220761865
- Email: zj2020email@163.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Recruiting
- The First Affiliated Hospital of Xi'an Jiao Tong University
-
Contact:
- zi liu, Ph.D
- Phone Number: +8613630223132
- Email: liuzmail@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age ≥18;
- Evidence of histological diagnosis of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
- Pathology or imaging suggested recurrence, with measurable lesions, and the number of lesions ≤3;
- No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney and immune deficiency
- Cooperative Oncology Group-Status (ECOG Status) score 0-2;
- Expected survival ≥3 months;
- Feasible abdomen and pelvic cavity MRI/CT;
- Good compliance, signed informed consent voluntarily.
Exclusion Criteria:
- Previous radiotherapy at the target lesion site;
- History of active inflammatory bowel disease or severe stomach and duodenal ulcers;
- Human immunodeficiency virus (HIV) infected persons;
- active hepatitis b (HBVDNA quantitative test results exceed the lower limit), or HCV infection (HCVRNA quantitative test results exceed the lower limit);
- suffering from serious underlying diseases, including but not limited to active infections requiring systemic medication:
- patients with a history of other malignant tumors (except cured basal cell carcinoma of the skin);
- neurological or mental disorders that affect cognitive ability;
- Patients whose lesions have been evaluated by the investigator and cannot be treated with external irradiation or endovascular radiation therapy;
- those who cannot follow up regularly as prescribed by the doctor;
- Other reasons not suitable for participating in this study as judged by the researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A (drug treatment group)
Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
|
Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
|
Experimental: Group B (radiotherapy group)
IFRT, IMRT or SBRT is applied.
Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.
|
IFRT(involving field radiotherapy) IMRT ( intensity modulated radiation therapy) SBRT (stereotactic body radiation therapy)
|
Experimental: Group C (radiotherapy + drug group)
Drug therapy is the same as group A; IFRT is the same as group B.
|
Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
IFRT(involving field radiotherapy) IMRT ( intensity modulated radiation therapy) SBRT (stereotactic body radiation therapy)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Control ( LC )
Time Frame: 6 months
|
LC will be measured from the start date of treatment until the date of progressive of the target lesion
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival ( PFS )
Time Frame: 24 months
|
PFS is defined as the time from first day of treatment until the first date of either objective disease progression or death due to any cause
|
24 months
|
Overall Survival ( OS )
Time Frame: 24 months
|
OS is defined as the time from first day of treatment until the date of death due to any cause or the deadline for the study
|
24 months
|
Rate of Radiation-related Adverse Reactions
Time Frame: 24 months
|
Rate of acute and late adverse reactions associated with radiotherapy
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Zi Liu, Ph.d, First Affiliated Hospital Xi'an Jiaotong University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 10, 2021
Primary Completion (Anticipated)
February 28, 2023
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
September 13, 2021
First Submitted That Met QC Criteria
September 25, 2021
First Posted (Actual)
September 28, 2021
Study Record Updates
Last Update Posted (Actual)
September 28, 2021
Last Update Submitted That Met QC Criteria
September 25, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Neoplastic Processes
- Neoplasms
- Neoplasm Metastasis
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Dermatologic Agents
- Keratolytic Agents
- Coal Tar
Other Study ID Numbers
- GCR-04
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on chemotherapy, targeted therapeutics, immunotherapy
-
Fundación Sociedad Española de Oncologia MédicaRecruiting
-
Shanghai Pudong HospitalDuke UniversityRecruitingMetastatic Cancer | Advanced CancerChina
-
Zhejiang Cancer HospitalRecruitingMetastatic Breast Cancer in the LiverChina
-
Second Affiliated Hospital, School of Medicine,...Hebei Medical University Fourth Hospital; Zhejiang University; Cancer Hospital...Not yet recruitingUnresectable Metastatic Colorectal Cancer
-
Shanghai Chest HospitalRecruitingThymic Carcinoma | Thymic Epithelial Tumor | Thymic CancerChina
-
Prince of Songkla UniversityRecruiting
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
ShiCang YuRecruiting
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Karolinska University Hospital; Oslo University Hospital; St Vincent's University...CompletedMelanoma | Urogenital Neoplasms | Breast Cancer | Head and Neck Cancer | Lung CancerItaly
-
Shanghai Chest HospitalRecruitingNon Small Cell Lung CancerChina